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Background: The antiviral protein Daxx acts as a restriction factor of avian sarcoma virus (ASV; Retroviridae) in
mammalian cells by promoting epigenetic silencing of integrated proviral DNA. Although Daxx is encoded by a
type I (α/β) interferon-stimulated gene, the requirement for Daxx in the interferon anti-retroviral response has not
been elucidated. In this report, we describe the results of experiments designed to investigate the role of Daxx in
the type I interferon-induced anti-ASV response.
Findings: Using an ASV reporter system, we show that type I interferons are potent inhibitors of ASV replication.
We demonstrate that, while Daxx is necessary to silence ASV gene expression in the absence of interferons, type I
interferons are fully-capable of inducing an antiviral state in the absence of Daxx.
Conclusions: These results provide evidence that Daxx is not essential for the anti-ASV interferon response in
mammalian cells, and that interferons deploy multiple, redundant antiviral mechanisms to protect cells from ASV.
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Introduction
Avian SarcomaVirus (ASV) is a prototypic alpharetrovirus
(family Retroviridae) that can be pseudotyped to transduce
mammalian cells and study host antiviral responses. We
have previously shown that the cellular scaffolding protein
Daxx, originally identified a mediator of death-receptor-
triggered apoptosis [1], is also a potent anti-ASV restric-
tion factor [2]. Daxx is recruited to viral DNA by ASV
integrase, where it promotes the rapid epigenetic repres-
sion of integrated viral DNA via recruitment of gene-
repressive histone deacetylases (HDACs) and DNA methyl
transferases [2,3]. We identified an essential role for Daxx
in controlling ASV replication by demonstrating that gen-
etic ablation or RNA interference-mediated knockdown of
Daxx expression resulted in significantly-increased expres-
sion of an ASV-encoded reporter gene [2,3].* Correspondence: richard.katz@fccc.edu; siddharth.balachandran@fccc.edu
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unless otherwise stated.Type I (predominantly α/β) interferons (IFNs), are a
family of cytokines with powerful antiviral and immune-
modulatory effects, and are rapidly induced in most cells
upon virus infection. Once produced, IFNs activate an
antiviral state in the infected cell, as well as in surroun-
ding cells, by Jak/STAT-regulated induction of >1000 IFN-
stimulated genes (ISGs) [4,5]. Daxx mRNA and protein
expression are induced following exposure to type I IFNs,
indicating that Daxx is an ISG [2,3].
Here, we demonstrate that type I IFNs are powerful
inhibitors of ASV replication in human and avian cells.
We show that, although Daxx is upregulated by type I
IFNs and essential on its own for silencing ASV gene
expression in human cells, it is largely dispensable for
establishment of the type I IFN-induced anti-retroviral
state. Our results suggest that IFNs are capable of effect-
ively inhibiting ASV even in the absence of Daxx, pro-
viding evidence that epigenetic silencing by Daxx is a
redundant mechanism of the IFN anti-ASV response in
mammalian cells.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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To investigate whether type I IFNs can block the early
steps in ASV replication, we treated HeLa cells with
either human IFN-α or IFN-β prior to infection with an
ASV-GFP reporter virus. This reporter virus is pseudo-
typed to express the murine leukemia virus (MuLV) am-
photropic envelope protein, and is therefore capable of
entry into mammalian cells. ASV-GFP contains an intact
complement of replicative genes, and is fully-capable of
productive infection in its natural avian host cells, but
several post-transcriptional blocks in mammalian cells
inhibit late events in the virus life-cycle, limiting infec-
tion to a single round in these cells [2,3]. ASV-GFP infec-
tion of mammalian cells, however, recapitulates key early
events of the retroviral life-cycle, including entry, uncoat-
ing, reverse-transcription and integration. As diminished
GFP expression is a faithful readout of Daxx-dependent si-
lencing, we have previously employed ASV-GFP to iden-
tify post-integration silencing of retroviral gene-expression
as a Daxx-sensitive step [2,3].
After treating HeLa cells with either IFN-α or IFN-β
for 18 h, we infected these cells with ASV-GFP in the
presence of DEAE-Dextran (20 μg/mL), as described
previously [6], and quantified viral gene expression by
measuring GFP fluorescence 48 h post-infection. As the
IFN-induced antiviral state is rarely maintained for more
than 30 h post-treatment [7], cells were supplementedFigure 1 Type I IFNs inhibit ASV replication. (A) Fluorescence-activated
GFP-positive cells) in untreated, human IFN-α (1000 U/ml)- or human IFN-β
experiment. GFP fluorescence data were collected on an LSR II flow cyt
FSC = Forward scatter. (B) Quantification of GFP-positive cells from four ind
represent mean +/− standard deviation. * p <0.05. (C) VSV-GFP replication (in
(1000 U/ml)-treated HeLa cells 24 h post-infection from a representative expe
independent replicates of the experiment described in panel C. Error bars repwith IFN 6 h and 24 h post infection. Vesicular stomatitis
virus encoding GFP (VSV-GFP) [8] was used as a positive
control for IFN activity, as VSV is a well-established IFN-
sensitive virus [9,10]. We found that treatment of HeLa
cells with either IFN-α or IFN-β efficiently diminished
GFP positivity (by ~70% and ~85%, respectively) following
ASV infection, demonstrating that type I IFNs are capable
of blocking ASV gene expression (Figure 1A,B). As ex-
pected, IFN-α and IFN-β inhibited VSV-GFP replication
almost completely (from >75% GFP-positive cells in un-
treated controls to <1% GFP-positive cells after IFN-α/β
treatment; Figure 1C,D).
Type I IFNs Inhibit ASV replication in avian cells
To extend this investigation to cells of natural ASV hosts,
we performed similar experiments in DF-1 chicken cells.
We limited ASV replication to a single round in these
cells by using a self-inactivating ASV-based alphare-
troviral GFP-transducing vector with diminished LTR
transcriptional activity [11]. After treating DF-1 cells with
chicken IFN-α for 18 h, we infected these with 5 μL of
self-inactivating ASV-GFP in the presence of Polybrene
(10 μg/mL) at 37°C for 1 h. To ensure continued mainten-
ance of the antiviral state, we supplemented cells with
IFN-α 6 h and 24 h p.i. When we examined these cells by
GFP-based flow cytometry 48 h p.i., we observed that
treatment with chicken type I IFN diminished proviralCell Sorter (FACS) analysis of ASV-GFP replication (indicated by %
(1000 U/ml)-treated HeLa cells 48 h post-infection from a representative
ometer (Becton Dickinson), and analyzed using FlowJo software.
ependent replicates of the experiment described in panel A. Error bars
dicated by % GFP-positive cells) in untreated, IFN-α (1000 U/ml)- or IFN-β
riment. (D) Quantification of GFP-positive cells from four
resent mean +/− standard deviation. ***p <0.001.
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Figure 2), as observed in mammalian cells (Figure 1A-D).
Collectively, these results demonstrate that type I IFNs
exert antiviral activity against ASV, and set the stage for ex-
periments designed to determine if Daxx is an essential
component of the IFN anti-ASV program.
Daxx is induced by type I IFNs in mammalian and
avian cells
We previously demonstrated that treatment with IFN-α
results in induction of Daxx mRNA in HeLa cells [3].
To evaluate Daxx protein levels following IFN treatment,
we treated HeLa or DF-1 cells with either human or
chicken IFN-α, respectively, and examined whole-cell ly-
sates prepared from these cells at various times post-
treatment by immunoblotting. As shown in Figure 3A,
IFN treatment increased Daxx protein levels ~3-fold by
24 h in HeLa cells. In DF-1 cells, IFN-α induction of
Daxx was confirmed to occur at the mRNA level (~2.5-
fold, Figure 3B). A protein band of the approximate size
of the putative avian Daxx ortholog was similarly induced
by chicken IFN-α (Figure 3C). Thus, Daxx is an IFN-
inducible protein in both mammalian and avian cells.
Daxx is not essential for type I IFN-mediated inhibition of
ASV replication in mammalian cells
To directly determine if Daxx contributed non-redundantly
to the IFN-induced antiviral state in mammalian cells, we
knocked-down Daxx expression by RNAi. Individual or
pooled transfection of HeLa cells with four distinct siR-
NAs that target Daxx mRNA reduced Daxx protein levels
in HeLa cells to nearly-undetectable levels within 72 h of
treatment (Figure 4A). By contrast, Daxx levels in cells
transfected with control non-silencing siRNAs were com-
parable to those seen in untreated HeLa cells (Figure 4A).
To determine whether Daxx knockdown resulted in an
altered ISG induction profile following IFN treatment,
we transfected HeLa cells with control or pooled DaxxFigure 2 Chicken IFN-α inhibits ASV replication in DF-1 cells. (A) FACS
untreated or chicken IFN-α (1000 U/ml)-treated DF-1 cells 48 h post-infection fro
of GFP-positive cells from three independent replicates of the experiment descr
*p <0.05.siRNAs, treated these cells with IFN-α, and analyzed
lysates from these cells by immunoblotting. Knockdown
of Daxx did not significantly alter the kinetics or mag-
nitude of STAT1 phosphorylation by IFN-α (Figure 4B).
Over a longer time course of 24 h, Daxx knockdown did
not affect the kinetics of induction of prototypic ISG-
encoded proteins STAT1 and MX1, and only modestly af-
fected the magnitude of their induction (Figure 4C).
Together, these results indicate that loss of Daxx does
not significantly alter IFN-α-induced transcription.
To test if Daxx was required for IFN-mediated anti-
viral activity against ASV, we first transfected HeLa cells
with either non-silencing siRNAs, or with a pool of the
four siRNAs that target Daxx, and exposed these cells to
IFN-α or IFN-β 54 h post-transfection. At 72 h post-
siRNA transfection (and 18 h post IFN treatment) when
Daxx knockdown was maximal (Figure 4A), cells were
infected with ASV-GFP and supplemented with IFN 6 h
and 24 h p.i., before analysis by flow cytometry at 48 h
p.i. Consistent with previous findings, ASV reporter gene
expression was higher in Daxx-knockdown cells compared
to those treated with nonspecific siRNA (by about two-
fold, Figure 4D,E). However, both IFN-α and IFN-β re-
duced ASV-GFP expression to approximately the same
levels (~5% by IFN-α and ~3% by IFN-β) in cells trans-
fected with siRNA to Daxx as they did in cells carrying
non-silencing siRNAs (Figure 4D,E). These results provide
evidence that Daxx is not essential for IFN-mediated pro-
tection against ASV in mammalian cells.
Conclusions
The two salient findings of this study are that (1) type I
IFNs can potently inhibit ASV replication in mammalian
and avian cells, and (2) that although Daxx is IFN-
inducible, IFN-mediated anti-ASV activity in mammalian
cells does not require Daxx. Together with our previous
demonstration that Daxx is essential for anti-retroviral
host defense in the absence of IFNs [2,3], our currentanalysis of ASV-GFP replication (indicated by % GFP-positive cells) in
m a representative experiment. FSC = Forward scatter. (B) Quantification
ibed in panel A. Error bars represent mean +/− standard deviation.
Figure 3 Daxx is induced by type I IFNs. (A) Immunoblot analysis of Daxx protein levels (antibody from Sigma) after human (h) IFN-α (1000 U/ml)
treatment of HeLa cells for the indicated time points. (B) Real-time PCR showing Daxx mRNA levels in DF-1 cells following treatment with chicken (ch)
IFN-α for the indicated time points. Values were normalized to GAPDH. (C) Immunoblot analysis of Daxx protein levels following chicken (ch) IFN-α
treatment of DF-1 cells for the indicated times. β-actin (antibody from Sigma) is shown as a loading control. Molecular-weight markers, in kilodaltons,
are shown to the left of each blot.
Figure 4 Daxx is not required for type IFN inhibition of ASV replication in mammalian cells. (A) Immunoblot showing Daxx protein levels
in HeLa cells following transfection of four individual (lanes 2–5) or pooled (lane 6) siRNAs to human Daxx. Lane 1 = untreated control. Molecular
weight markers, in kilodaltons, are shown to the left. β-actin was used as a loading control. (B) Immunoblot analysis of STAT1 phosphorylation
following IFN-α treatment of HeLa cells transfected with nonspecific (N.S.) or pooled Daxx siRNAs. Cells were treated with IFN-α (1000 U/ml) for
the indicated time points. β-actin was used as a loading control. (C) Immunoblot analysis of STAT1 and MX1 induction following IFN-α treatment
of HeLa cells transfected with nonspecific (N.S.) or pooled Daxx siRNAs. (D) ASV-GFP replication (indicated by % GFP-positive cells) in untreated,
human IFN-α (1000 U/ml)- or human IFN-β (1000 U/ml)-treated HeLa cells 48 h post-infection. Cells were transfected with nonspecific (NS) or
Daxx siRNAs for 72 h prior to infection, as indicted to the left. FACS data from are representative experiment are shown. FSC = Forward scatter.
(E) Quantification of GFP-positive cells from three independent replicates of the experiment described in panel D. Error bars represent mean +/−
standard deviation. **p <0.01. n.s., not significant.
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Daxx protects against ASV (by epigenetic repression of
ASV proviral gene expression) prior to induction of IFNs.
Once induced, type I IFNs can establish an anti-retroviral
state in which Daxx is not essential.
A Daxx ortholog has been identified in Drosophila
and other insects [12], predating by ~150 million years
the emergence of IFN-α/β genes, which can be traced
back ~250 million years to the time when reptiles and
birds diverged from each other [13,14]. It is thus possible
that Daxx represents an ancient, metazoan anti-retroviral
protein the function of which remains essential in the ab-
sence of IFNs, but which has since been rendered redun-
dant by the relatively-recent emergence of the type I IFN
system in higher vertebrates.
Alternatively, our finding that IFN-mediated protec-
tion against ASV is Daxx-independent may be explained
simply by activation of mechanistically distinct, but func-
tionally redundant ISGs. Indeed, dependence on a single
ISG may be detrimental to the host in the face of a virus
infection, as viruses are capable of rapid evolution and
consequent subversion of antiviral host proteins. Several
viruses are known to target Daxx. For example, the human
cytomegalovirus (HCMV) virion tegument protein pp71,
as well as the adenovirus E1B-55 K protein have been
shown to induce degradation of Daxx via the proteasome
[15]. Redundant antiviral mechanisms ensure that mul-
tiple host defense strategies are in place, should any one,
e.g. Daxx, be compromised by virus infection. We specu-
late that in mammalian cells, IFNs target multiple early
steps in the ASV life cycle upstream of where Daxx is pro-
posed to act, including entry, capsid disassembly, uncoat-
ing, nuclear entry/reverse transcription, and integration.
As IFNs are capable of anti-ASV activity even in the
absence of Daxx, epigenetic repression of proviral DNA
by Daxx likely represents only one of the many diverse
pathways, including those activated by APOBEC3G,
TRIM5, TRIM22, and MXB, which are deployed by IFNs
to restrict early steps of retroviral replication [16-18]. For
example, APOBEC3G triggers damaging hypermutation
of retroviral cDNA following reverse transcription, TRIM5
blocks HIV-1 by inhibiting viral cDNA synthesis, and
MXB has been reported to inhibit HIV-1 DNA integration
[16-18]. Induction of these or similar restriction factors
may account for IFN-mediated protection against ASV in
the absence of Daxx.
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